Regulatory

CIRS RD Briefing 45: Regulatory timelines in Saudi Arabia

This unique study is the first in-depth analysis of the trends and changes in the regulatory approval times for medicines in the Kingdom of Saudi Arabia. Not only have [...]

2025-03-20T16:44:53+00:00September 1st, 2004|Tags: , |

CIRS RD Briefing 42: Changing regulatory environment

A summary of the outcome of a survey carried out by the CMR International Institute for Regulatory Science among pharmaceutical companies and regulatory agencies. There was consensus that the [...]

2021-01-29T11:49:19+00:00August 1st, 2004|Tags: |

CIRS RD Briefing 41 – Workshop on Regulatory Performance

Highlights from the workshop entitled 'Regulatory Performance: Critical Success Factors in Today’s Environment', held by the CMR International Institute for Regulatory Science in Washington D.C., 15-16 September 2003 In [...]

2026-01-05T16:49:34+00:00April 1st, 2004|Tags: , |

CIRS RD Briefing 40 – Pharmacogenetics and pharmacogenomics in drug development

Summarised results of a survey carried out among pharmaceutical companies and regulatory agencies, by the CMR International Institute for Regulatory Science Pharmacogenetic (PGt) and pharmacogenomic (PGx) technologies are being [...]

2021-02-08T16:35:20+00:00December 2nd, 2003|Tags: |

CIRS RD Briefing 39 – Regulating personalised medicine

Highlights of the workshop "Regulating personalised medicine" organised by the CMR International Institute for Regulatory Science, Nutfield Priory, Surrey, UK, 14-15 April 2003 The unravelling of the human genome [...]

2026-01-05T16:57:16+00:00December 1st, 2003|Tags: , |

CIRS RD Briefing 38 – Risk management

Highlights of the CMR International institute Workshop on 'Risk Management: Identifying and Developing Effective Stakeholder Communication During Drug Development', held on 12-13 December 2002. Following a number of high [...]

2026-01-05T16:54:36+00:00June 1st, 2003|Tags: , , |
Go to Top